Psilocybin availability in the UK

Posted Posted in Depression, Digital Health, Psychedelic-Assisted Psychotherapy

It is no secret in the medical sector, that evidence for the efficacy of traditional antidepressants (SSRIs, SNRIs, NASSAs…) is underwhelming. In 2018, the largest ever meta-analysis concluded that the majority of their effect, if any, can be attributed to placebo¹. That being said, the clinical rationale for taking them is still sound, as prescribing […]

Can pharmacists prescribe cannabis-based medicines?

Posted Posted in Digital Health, New Medicines, Psychedelic-Assisted Psychotherapy

Currently, prescribing pharmacists in the UK cannot prescribe cannabis-based products for medicinal use (CBPMs). Prescribing of CBPMs for medicinal use in the UK is restricted to only those clinicians listed on the Specialist Register of the General Medical Council¹. The GMC² does not specify what type of speciality is needed (there are over 60 possible […]

Esketamine availability in Australia

Posted Posted in Depression, Digital Health, New Medicines, Psychedelic-Assisted Psychotherapy

Spravato is the brand name of esketamine, a glutamate receptor drug used for rapid depression treatment manufactured by Johnson & Johnson in the US. Esketamine contained within the standard pharmaceutical form of ketamine, which has traditionally been used at higher doses as an anaesthetic. The difference between Esketamine and Ketamine is that the latter contains the […]